RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight granted inducement stock options on 236,456 shares to two new non-executive officer employees at an exercise price of $5.02, the grant-date closing price. It also agreed to grant RSUs covering 637,449 shares to the same employees on or about November 3, 2026, under its 2026 Inducement Equity Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
Key figures
- Inducement rsu shares
- 637449
- Option exercise price
- 5.02
- Inducement options shares
- 236456
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.